Valion Bio, Inc. Impairment of Long-Lived Assets Held-for-use
Valion Bio, Inc. (VBIO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-11-14
- Valion Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-03-31 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Valion Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-21 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-25 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |